We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Prognostic Biomarker Candidates Identified for Ovarian Cancer

By LabMedica International staff writers
Posted on 25 Nov 2014
Print article
Image: Histopathology of ovarian serous papillary borderline tumor, intracystic, without surface cortical involvement (Photo courtesy of Brown University).
Image: Histopathology of ovarian serous papillary borderline tumor, intracystic, without surface cortical involvement (Photo courtesy of Brown University).
Two independent classes of novel candidate prognostic markers for ovarian cancer have been identified advancing efforts to develop targeted therapies for the disease.

An association of this often-deadly cancer has been made with the immune system and clarified the role of a class of immunogenic tumor antigens known as cancer testis (CT) antigens, as the immune system can potently inhibit the growth of cancer cells. These novel findings may enable development of a new strategy for identifying those patients most likely to benefit from particular targeted therapies.

Scientists at the Roswell Park Cancer Institute (Buffalo, NY, USA) establish novel associations between prognosis and the expression of immune-related genes through a focused screen utilizing publicly available high-throughput assays. The Cancer Genome Atlas (TCGA; Bethesda, MD, USA) is a biorepository study of high-grade serous ovarian cancers from multiple centers in the USA and relevant to their analysis, the study strictly included ovarian primaries and papillary serous histologies.

The team found preliminary evidence that some CT antigens are associated with survival when examined in concert with the five-gene signature. Fifteen of 64 immune-related genes were associated with survival of which five were reproduced in a validation set. The expression of these genes defines an immunoreactive (IR) subgroup of patients with a favorable prognosis. Phenotypic characterization of the immune compartment signal includes upregulation of markers of CD8+ T-cell activation in these patients.

Takemasa Tsuji, PhD, an assistant professor of Oncology and co-author of the study said, “CT antigens like the cancer-testis antigen NY-ESO-1 are readily recognized by the immune system and are therefore prime targets for cancer immunotherapies, so this work unveiling interaction between cancer and immune cells has real implications for our development of efficient immunotherapies at the Center for Immunotherapy. Determining patterns of both the immunological markers and CT antigens present in a women's tumor can lead the way to personalized medicine, an approach that uses the best combination of therapeutic modality and target antigen.” The study was published on November 7, 2014, in the journal Public Library of Science ONE.

Related Links:

Roswell Park Cancer Institute 
The Cancer Genome Atlas 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.